Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!
Canada is the first country in the world to approve a cannabis spray that relieves pain in people with multiple sclerosis, Health Canada said Tuesday.
The announcement sent shares of the U.K. maker of the drug, GW Pharmaceuticals Plc, up as much as 14 per cent in London. Bayer AG will market the drug in Canada.
Sativex, which is administered through a spray in the mouth, relieves pain in patients that suffer from MS, the government agency said. It's expected to hit the shelves by late spring.
"Effective pain control and management are extremely important in a disease like MS," said Dr. Allan Gordon, neurologist and director of the Wasser Pain Management Centre at Mount Sinai Hospital in Toronto, in a statement. "The approval of Sativex in Canada reflects the urgent need for additional treatment options in the field of neuropathic pain in MS."
Neuropathic pain, or nerve pain, is a common symptom of MS and can occur in as many as 86 per cent of people with the disease, Health Canada said.
The drug is derived from two compounds, delta-9- tetrahydrocannabinol and cannabidiol.
About 50,000 Canadians have MS and the disease of the central nervous system is the most common neurological disease affecting young adults in Canada.